Published in Childs Nerv Syst on September 16, 2006
CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics (2007) 2.11
A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet (2008) 2.02
Stabilization of VEGFR2 signaling by cerebral cavernous malformation 3 is critical for vascular development. Sci Signal (2010) 1.68
CCM1 gene deletion identified by MLPA in cerebral cavernous malformation. Neurosurg Rev (2006) 0.93
High mutation detection rates in cerebral cavernous malformation upon stringent inclusion criteria: one-third of probands are minors. Mol Genet Genomic Med (2014) 0.91
Predictive genetic testing of at-risk relatives requires analysis of all CCM genes after identification of an unclassified CCM1 variant in an individual affected with cerebral cavernous malformations. Neurosurg Rev (2013) 0.83
A retrospective and consecutive analysis of the epidemiology and management of spinal cavernomas over the last 20 years in a single center. Neurosurg Rev (2015) 0.82
A founder mutation in the Ashkenazi Jewish population affecting messenger RNA splicing of the CCM2 gene causes cerebral cavernous malformations. Genet Med (2011) 0.75
Truncating mutations in CCM1, encoding KRIT1, cause hereditary cavernous angiomas. Nat Genet (1999) 2.79
Mutations within the programmed cell death 10 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 2.62
Mutations in a gene encoding a novel protein containing a phosphotyrosine-binding domain cause type 2 cerebral cavernous malformations. Am J Hum Genet (2003) 2.58
Mutations within the MGC4607 gene cause cerebral cavernous malformations. Am J Hum Genet (2004) 1.88
Mutations in apoptosis-related gene, PDCD10, cause cerebral cavernous malformation 3. Neurosurgery (2005) 1.59
Cerebral cavernomas in the adult. Review of the literature and analysis of 72 surgically treated patients. Neurosurg Rev (2002) 1.53
Cerebral cavernous malformations: mutations in Krit1. Neurology (2002) 1.27
Spectrum and expression analysis of KRIT1 mutations in 121 consecutive and unrelated patients with Cerebral Cavernous Malformations. Eur J Hum Genet (2002) 1.25
Hereditary cerebral cavernous angiomas: clinical and genetic features in 57 French families. Société Française de Neurochirurgie. Lancet (1998) 1.25
Low frequency of PDCD10 mutations in a panel of CCM3 probands: potential for a fourth CCM locus. Hum Mutat (2006) 1.24
Intracranial cavernous angioma: a practical review of clinical and biological aspects. Surg Neurol (2005) 1.18
Germline mutations in the CCM1 gene, encoding Krit1, cause cerebral cavernous malformations. Ann Neurol (2001) 1.14
Clinical features of cerebral cavernous malformations patients with KRIT1 mutations. Ann Neurol (2004) 1.12
CCM3 mutations are uncommon in cerebral cavernous malformations. Neurology (2005) 1.03
CCM1 mutation screen of sporadic cases with cerebral cavernous malformations. Neurology (2004) 0.90
CCM2 mutations account for 13% of cases in a large collection of kindreds with hereditary cavernous malformations. Ann Neurol (2004) 0.87
Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. Science (2005) 7.07
CCM3 interacts with CCM2 indicating common pathogenesis for cerebral cavernous malformations. Neurogenetics (2007) 2.11
A two-hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet (2008) 2.02
Cavernoma-related epilepsy: review and recommendations for management--report of the Surgical Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia (2013) 2.00
Functional analyses of human and zebrafish 18-amino acid in-frame deletion pave the way for domain mapping of the cerebral cavernous malformation 3 protein. Hum Mutat (2009) 1.90
Cerebral cavernous malformation protein CCM1 inhibits sprouting angiogenesis by activating DELTA-NOTCH signaling. Proc Natl Acad Sci U S A (2010) 1.61
Cerebral cavernomas in the adult. Review of the literature and analysis of 72 surgically treated patients. Neurosurg Rev (2002) 1.53
Subdural drainage versus subperiosteal drainage in burr-hole trepanation for symptomatic chronic subdural hematomas. World Neurosurg (2011) 1.52
Molecular classification of low-grade diffuse gliomas. Am J Pathol (2010) 1.51
Effective surgical treatment of cerebral cavernous malformations: a multicenter study of 79 pediatric patients. J Neurosurg Pediatr (2011) 1.45
Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in-frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat (2008) 1.31
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma. Oncotarget (2013) 1.17
Endoscopic third ventriculostomy for obstructive hydrocephalus. Neurosurg Rev (2004) 1.16
Seizure outcome after resection of supratentorial cavernous malformations: a study of 168 patients. Epilepsia (2007) 1.12
Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res (2004) 1.05
Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations. Brain Pathol (2011) 1.00
Implication of PTEN in production of reactive oxygen species and neuronal death in in vitro models of stroke and Parkinson's disease. Neurochem Int (2006) 0.98
Immunohistochemical study in dural arteriovenous fistulas and possible role of local hypoxia for the de novo formation of dural arteriovenous fistulas. Clin Neurol Neurosurg (2004) 0.97
Proteomic analysis of cathepsin B- and L-deficient mouse brain lysosomes. Biochim Biophys Acta (2007) 0.97
Differential angiogenesis function of CCM2 and CCM3 in cerebral cavernous malformations. Neurosurg Focus (2010) 0.97
Enlarged perivascular spaces mimicking multicystic brain tumors. Report of two cases and review of the literature. J Neurosurg (2005) 0.97
Neuroendoscopic treatment for colloid cysts of the third ventricle: the experience of a decade. Neurosurgery (2003) 0.96
Is the image guidance of ultrasonography beneficial for neurosurgical routine? Surg Neurol (2007) 0.96
Surgical closure and reconstruction of a large occipital encephalocele without parenchymal excision. Childs Nerv Syst (2004) 0.95
Spontaneous cerebellar hemorrhage--experience with 57 surgically treated patients and review of the literature. Neurosurg Rev (2010) 0.95
Image-guided transsylvian, transinsular approach for insular cavernous angiomas. Neurosurgery (2003) 0.95
Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment. Strahlenther Onkol (2006) 0.95
The venous angioarchitecture of sporadic cerebral cavernous malformations: a susceptibility weighted imaging study at 7 T MRI. J Neurol Neurosurg Psychiatry (2012) 0.95
Intraoperative ultrasound assistance in treatment of intradural spinal tumours. Clin Neurol Neurosurg (2011) 0.94
Neuroform stent-assisted treatment of intracranial aneurysms: long-term follow-up study of aneurysm recurrence and in-stent stenosis rates. Neuroradiology (2013) 0.94
CCM1 gene deletion identified by MLPA in cerebral cavernous malformation. Neurosurg Rev (2006) 0.93
TTM-based counselling in physiotherapy does not contribute to an increase of adherence to activity recommendations in older adults with chronic low back pain--a randomised controlled trial. Eur J Pain (2006) 0.92
Frequent BRAF gain in low-grade diffuse gliomas with 1p/19q loss. Brain Pathol (2012) 0.92
Loss of CCM3 impairs DLL4-Notch signalling: implication in endothelial angiogenesis and in inherited cerebral cavernous malformations. J Cell Mol Med (2013) 0.92
Prevalence of THAP1 sequence variants in German patients with primary dystonia. Mov Disord (2010) 0.91
Transsulcal approach supported by navigation-guided neurophysiological monitoring for resection of paracentral cavernomas. Clin Neurol Neurosurg (2008) 0.91
Evidence for anti-angiogenic and pro-survival functions of the cerebral cavernous malformation protein 3. Neurogenetics (2010) 0.90
Caudal image contrast inversion in MPRAGE at 7 Tesla: problem and solution. Acad Radiol (2011) 0.90
Neuroendoscopic treatment for colloid cysts of the third ventricle: the experience of a decade. Neurosurgery (2008) 0.89
Neurosurgical considerations on highly eloquent brainstem cavernomas during pregnancy. Clin Neurol Neurosurg (2012) 0.89
Do iatrogenic factors bias the placement of external ventricular catheters?--a single institute experience and review of the literature. Neurol Med Chir (Tokyo) (2011) 0.89
Studies of the brain specificity of S100B and neuron-specific enolase (NSE) in blood serum of acute care patients. Brain Res Bull (2003) 0.89
Pontine hemorrhage. J Neurosurg (2003) 0.89
Susceptibility weighted magnetic resonance imaging of cerebral cavernous malformations: prospects, drawbacks, and first experience at ultra-high field strength (7-Tesla) magnetic resonance imaging. Neurosurg Focus (2010) 0.89
Neuroendoscopic surgery of intracranial cysts in adults. Childs Nerv Syst (2004) 0.89
Immune surveillance of the human central nervous system (CNS): different migration pathways of immune cells through the blood-brain barrier and blood-cerebrospinal fluid barrier in healthy persons. Cytometry A (2006) 0.88
Intraoperative ultrasound to define focal cortical dysplasia in epilepsy surgery. Epilepsia (2007) 0.88
Biological activity of adult cavernous malformations: a study of 56 patients. J Neurosurg (2005) 0.87
Correlation of aquaporin-1 water channel protein expression with tumor angiogenesis in human astrocytoma. Anticancer Res (2013) 0.87
Cavernoma of the trochlear nerve. Clin Neurol Neurosurg (2007) 0.87
Evaluation of hardware-related geometrical distortion in structural MRI at 7 Tesla for image-guided applications in neurosurgery. Acad Radiol (2011) 0.86
Implications of Dll4-Notch signaling activation in primary glioblastoma multiforme. Neuro Oncol (2013) 0.86
Surgery of intracranial aneurysms previously treated endovascularly. Clin Neurol Neurosurg (2007) 0.85
Circulating extracellular proteasome in the cerebrospinal fluid: a study on concentration and proteolytic activity. J Mol Neurosci (2011) 0.85
EGR-1 is regulated by N-methyl-D-aspartate-receptor stimulation and associated with patient survival in human high grade astrocytomas. Brain Pathol (2008) 0.85
Secretory meningioma: immunohistochemical findings and evaluation of mast cell infiltration. Neurosurg Rev (2005) 0.85
A loose screw or two. Lancet (2011) 0.85
Instable cervical spine injury in a toddler: technical note. Childs Nerv Syst (2010) 0.84
PTEN/PI3K/Akt/VEGF signaling and the cross talk to KRIT1, CCM2, and PDCD10 proteins in cerebral cavernous malformations. Neurosurg Rev (2014) 0.84
Impairment of tight junctions and glucose transport in endothelial cells of human cerebral cavernous malformations. J Neuropathol Exp Neurol (2011) 0.84
The role of underlying structural cause for epilepsy classification: clinical features and prognosis in mesial temporal lobe epilepsy caused by hippocampal sclerosis versus cavernoma. Epilepsia (2011) 0.84
Cerebral cavernous hemangiomas at 7 Tesla: initial experience. Acad Radiol (2009) 0.84
Involvement of PTEN promoter methylation in cerebral cavernous malformations. Stroke (2008) 0.84
Association of the CC genotype of the regulatory BCL2 promoter polymorphism (-938C>A) with better 2-year survival in patients with glioblastoma multiforme. J Neurosurg (2011) 0.84
Hypoxia-inducible factor and vascular endothelial growth factor are expressed more frequently in embolized than in nonembolized cerebral arteriovenous malformations. Neurosurgery (2004) 0.84
Predictive genetic testing of at-risk relatives requires analysis of all CCM genes after identification of an unclassified CCM1 variant in an individual affected with cerebral cavernous malformations. Neurosurg Rev (2013) 0.83
DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome. J Neuropathol Exp Neurol (2012) 0.83
Intraoperative landmarking of vascular anatomy by integration of duplex and Doppler ultrasonography in image-guided surgery. Technical note. Surg Neurol (2005) 0.83